Combination PET With 18F-fluorodeoxyglucose (18F-FDG) and 18 F-choline in Patient With HCC

Inclusion Criteria: * Patients\> 18 years old * First diagnosis of HCC (no previous treatments received) * Diagnosis of HCC according to The European Association for the Study of the Liver (EASL) 2012 criteria by "non-invasive" imaging on cirrhosis or by histology on cirrhosis or non-cirrhotic liver * BCLC tumor stage A to C (excluding BCLC C with extrahepatic metastases) according to conventional imaging * Will be able to have a PET scanner within 4 weeks after the inclusion visit * Ability to stay 20 minutes longer for PET-CT scans * Need for oral, intra-uterine or mechanical contraception for women of childbearing age * Written consent for participation in the study * Having medical insurance coverage Exclusion Criteria: * Patients classified BCLC stage 0 (single HCC less than 2 cm) * Patients classified as BCLC stage C with extrahepatic metastases * Decreased cirrhosis (Child Pugh C) and / or patients with Eastern Cooperative Oncology Group (ECOG) Performance Status 2 to 4 not candidates for liver transplantation * Uncontrolled diabetes (defined by blood glucose\> 1.7 g / L at the time of inclusion) * Hypersensitivity to 18F Fluorocholine or 18F-FDG or any of the excipients * Creatinine clearance \<40 mL / min * Contraindication to MRI: pacemaker or implantable cardiac defibrillator not compatible with MRI, neurostimulator, cochlear implant, intracerebral ferromagnetic vascular clip, intraocular or cerebral metallic foreign bodies, insulin pump * Pregnant or lactating …